JP2005525407A - 細胞及び作用物質を担持する微小粒子 - Google Patents
細胞及び作用物質を担持する微小粒子 Download PDFInfo
- Publication number
- JP2005525407A JP2005525407A JP2004500842A JP2004500842A JP2005525407A JP 2005525407 A JP2005525407 A JP 2005525407A JP 2004500842 A JP2004500842 A JP 2004500842A JP 2004500842 A JP2004500842 A JP 2004500842A JP 2005525407 A JP2005525407 A JP 2005525407A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- microparticle
- cell
- microparticles
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
−それらは、細胞(又はその断片)の培養用担体として役立ち得る。移植する細胞の微小粒子に対する好ましい付着により、それらを採集するために、明白な、衛生上の安全の理由で勧められない動物由来のタンパク質分解酵素を使用せずに、それらの調製、更にはそれらの試験管内形質転換が可能になる。
−それらは、移植細胞(又は細胞分画)への担体として役立ち、かつ埋め込み後に毒性なしに分解し得、移植細胞(又はその断片)の組み込みに干渉しない。
−それらは、プログラムされた期間に、かつ一定の分量で1つ又は幾つかの成長因子又はサイトカインを放出し得る。
−それらは、移植細胞の生存率及び分化を促進し、その微小環境、並びに宿主組織中へのそれらの組み込みを変更し得る。
−(血液幹細胞から生じた樹状細胞による予防接種の範囲で)試験管内で樹状細胞と接触させられるためであるか、
−皮下、真皮内、又は筋肉内から患者の直接投与されるためである。
回収された膜タンパク質の量を決定するために、ローリーテストを実施する分量決定が、行われた。(0.2〜1μg/μLの)BSAの基準範囲を使用して、試料のタンパク質濃度を計算することができた。精製開始時に(溶解の直後に)採取され、かつ細胞のタンパク質の集合を含む、初期アリコート(Ai)と呼ばれるアリコートは、7000〜10000μg/μLのタンパク質濃度を示した。それに反して、濃縮終了時には、200〜300μg/μLのタンパク質濃度が得られる。従って我々は、タンパク質全体の3%を回収した。
共焦点顕微鏡の膜マーカー(5’−ヌクレオチダーゼ、インテグリン、ICAM−1)の直接免疫蛍光法は、微小粒子に対する膜タンパク質の固定を確認する。
Claims (14)
- 生物活性物質を担持する、生体適合性かつ生分解性材料を主成分とする微小粒子であって、その表面に目的とする細胞又はその断片を含むこと、及び微小粒子の埋め込みの際に前記細胞又はその環境に対して少なくとも1つの作用物質の分子を含み、前記分子は、微小粒子によって、持続して、かつ制御されて放出されることを特徴とする微小粒子。
- 少なくとも1つの作用物質の分子が、表面にあり、かつ/又は微小粒子中に取り込まれることを特徴とする請求項1に記載の微小粒子。
- 生体適合性かつ生分解性材料は、ポリマー又はコポリマーであることを特徴とする請求項1又は2のいずれかに記載の微小粒子。
- ポリマー又はコポリマーは、ポリ(α−ヒドロキシ酸)、例えばポリラクチド、ポリラクチドco−グリコリド、ポリエステル、例えばポリε−カプロラクトン(poly ε−coprolactones)、ポリ(オルトエステル)、ポリ(ホスホゼン)(poly(phosphozenes))、PLGA及びそれらの混合物を含む群から選択されることを特徴とする請求項1から3のいずれかに記載の微小粒子。
- 約1〜500μm、かつ好適には10〜500μmの直径を有することを特徴とする請求項1から4のいずれかに記載の微小粒子。
- 生体適合性かつ生分解性材料は、目的とする細胞又はその断片の付着を可能にするか、又は細胞の付着を可能にする化合物でコーティングされ、前記化合物は、その上前記細胞又はその断片に対して場合により活性であることを特徴とする請求項1から5のいずれかに記載の微小粒子。
- 微小粒子表面の、目的とする細胞は:成人細胞、胚性細胞、形質転換された、又はされない細胞系統、幹細胞、遺伝子操作細胞、欠損組み換えウイルスを、それらの複製のために生成する細胞、肝細胞、ランゲルハンス島、神経細胞、筋細胞、造血細胞、骨細胞を含む群から選択されることを特徴とする請求項1から6のいずれかに記載の微小粒子。
- 微小粒子中に取り込まれた分子は、免疫調節物質、細胞の生存を促進する因子、細胞の毒剤、免疫反応及び拒絶を減少させて、又は血管形成を増加させ、組み込みを促進して組織環境に作用する因子、遺伝子操作細胞中に存在する遺伝子の発現を制御する因子を含む群から選択される少なくとも1つの作用物質のそれであることを特徴とする請求項1から7のいずれかに記載の微小粒子。
- 微小粒子中に取り込まれた分子は、成長因子、ホルモン、サイトカインを含む群から選択される少なくとも1つの作用物質のそれであることを特徴とする請求項1から8のいずれかに記載の微小粒子。
- 微小粒子表面の目的とする細胞は、抗原源として患者の腫瘍の初代培養から得られる自己腫瘍細胞であることを特徴とする請求項1から6のいずれかに記載の微小粒子。
- 微小粒子表面の細胞断片は、腫瘍の初代培養から得られるアポトーシス体又は膜小胞であることを特徴とする請求項1から6のいずれかに記載の微小粒子。
- 微小粒子中に取り込まれる分子は、炎症誘発性サイトカイン又はアジュバントを含む群から選択される少なくとも1つの作用物質のそれであることを特徴とする請求項10又は11のいずれかに記載の微小粒子。
- 組織修復又は遺伝子導入のための医薬品組成物を調製するための、生体適合性かつ生分解性材料を主成分とする微小粒子の使用であって、前記微小粒子は、その表面に目的とする細胞を含み、かつ微小粒子の埋め込みの際に前記細胞又はその環境に対して少なくとも1つの作用物質の分子を含み、前記分子は、微小粒子によって、持続して、かつ制御されて放出される使用。
- ワクチン、特には抗腫瘍医薬品組成物を調製するための、生体適合性かつ生分解性材料を主成分とする微小粒子の使用であって、前記微小粒子は、その表面に目的とする細胞又はその断片を含み、かつ微小粒子の埋め込みの際に前記細胞又はその環境に対して少なくとも1つの作用物質の分子を含み、前記分子は、微小粒子によって、持続して、かつ制御されて放出される使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/05574 | 2002-05-03 | ||
FR0205574A FR2839260B1 (fr) | 2002-05-03 | 2002-05-03 | Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives |
PCT/FR2003/001377 WO2003092657A1 (fr) | 2002-05-03 | 2003-05-02 | Microparticules supportant des cellules et des substances actives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011040940A Division JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005525407A true JP2005525407A (ja) | 2005-08-25 |
JP4819356B2 JP4819356B2 (ja) | 2011-11-24 |
Family
ID=29226179
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004500842A Expired - Lifetime JP4819356B2 (ja) | 2002-05-03 | 2003-05-02 | 細胞及び作用物質を担持する微小粒子 |
JP2011040940A Pending JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011040940A Pending JP2011153143A (ja) | 2002-05-03 | 2011-02-25 | 細胞及び作用物質を担持する微小粒子 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1507517B1 (ja) |
JP (2) | JP4819356B2 (ja) |
AU (1) | AU2003249390A1 (ja) |
CA (1) | CA2483707C (ja) |
ES (1) | ES2626204T3 (ja) |
FR (1) | FR2839260B1 (ja) |
WO (1) | WO2003092657A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011059112A1 (ja) * | 2009-11-13 | 2011-05-19 | 株式会社日立ハイテクノロジーズ | 粒子含有細胞集合体 |
JP2014518200A (ja) * | 2011-06-02 | 2014-07-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 膜で被包されたナノ粒子および使用方法 |
US10098839B2 (en) | 2014-03-20 | 2018-10-16 | The Regents Of The University Of California | Hydrogel toxin-absorbing or binding nanoparticles |
US10285952B2 (en) | 2013-08-08 | 2019-05-14 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
US10610493B2 (en) | 2015-04-29 | 2020-04-07 | The Regents Of The University Of California | Detoxification using nanoparticles |
WO2020203965A1 (ja) * | 2019-03-30 | 2020-10-08 | 国立大学法人九州大学 | 細胞接着用粒子及びその使用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050214377A1 (en) * | 2004-03-24 | 2005-09-29 | Sanjay Mistry | Microparticles for cell delivery |
WO2010033776A1 (en) * | 2008-09-18 | 2010-03-25 | Surmodics Pharmaceuticals, Inc. | Microencapsulation process with solvent and salt |
ES2612530T3 (es) | 2012-03-30 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composición de microesferas, método de preparación y aplicaciones de la misma |
WO2017221879A1 (ja) | 2016-06-20 | 2017-12-28 | 富士フイルム株式会社 | トロフィックファクタ放出剤および炎症疾患処置剤 |
CN111346236B (zh) * | 2018-12-21 | 2023-03-14 | 中国医学科学院生物医学工程研究所 | 负载肿瘤抗原的聚多巴胺纳米粒子及其制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193246A (ja) * | 1997-05-19 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 免疫増強製剤 |
JP2001010961A (ja) * | 1999-02-09 | 2001-01-16 | Inst Of Physical & Chemical Res | 腫瘍ワクチン |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470794A1 (fr) * | 1979-12-05 | 1981-06-12 | Pasteur Institut | Nouvelles microparticules, leur preparation et leurs applications en biologie, notamment a la culture de cellules diploides humaines |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
JPH04360682A (ja) * | 1991-06-06 | 1992-12-14 | Kurabo Ind Ltd | 細胞培養用担体 |
JPH0581A (ja) * | 1991-06-21 | 1993-01-08 | Koken Co Ltd | 細胞培養担体及び培養方法 |
GB9210574D0 (en) * | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
JPH09255777A (ja) * | 1996-03-21 | 1997-09-30 | Japan Synthetic Rubber Co Ltd | 担 体 |
US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
UA54505C2 (uk) * | 1997-04-03 | 2003-03-17 | Гілфорд Фармасьютікалз Інк. | Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання |
DK0981381T3 (da) * | 1997-05-12 | 2007-06-04 | Metabolix Inc | Polyhydroxyalkanoater ti anvendelser in vivo |
DE60120127T2 (de) * | 2000-03-20 | 2007-01-04 | Biosphere Medical, Inc., Rockland | Injizierbare mikrokügelchen für den gewebeaufbau |
-
2002
- 2002-05-03 FR FR0205574A patent/FR2839260B1/fr not_active Expired - Lifetime
-
2003
- 2003-05-02 JP JP2004500842A patent/JP4819356B2/ja not_active Expired - Lifetime
- 2003-05-02 ES ES03747486.3T patent/ES2626204T3/es not_active Expired - Lifetime
- 2003-05-02 WO PCT/FR2003/001377 patent/WO2003092657A1/fr active Application Filing
- 2003-05-02 AU AU2003249390A patent/AU2003249390A1/en not_active Abandoned
- 2003-05-02 CA CA2483707A patent/CA2483707C/fr not_active Expired - Lifetime
- 2003-05-02 EP EP03747486.3A patent/EP1507517B1/fr not_active Expired - Lifetime
-
2011
- 2011-02-25 JP JP2011040940A patent/JP2011153143A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193246A (ja) * | 1997-05-19 | 1999-07-21 | Sumitomo Pharmaceut Co Ltd | 免疫増強製剤 |
JP2001010961A (ja) * | 1999-02-09 | 2001-01-16 | Inst Of Physical & Chemical Res | 腫瘍ワクチン |
Non-Patent Citations (1)
Title |
---|
JPN6010001215, MAHONEY,M.J. et al, "Transplantation of brain cells assembled around a programmable synthetic microenvironment", Nat Biotechnol, 2001, Vol.19, No.10, p.934−9 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011059112A1 (ja) * | 2009-11-13 | 2011-05-19 | 株式会社日立ハイテクノロジーズ | 粒子含有細胞集合体 |
JP2014518200A (ja) * | 2011-06-02 | 2014-07-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 膜で被包されたナノ粒子および使用方法 |
US10285952B2 (en) | 2013-08-08 | 2019-05-14 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
US10098839B2 (en) | 2014-03-20 | 2018-10-16 | The Regents Of The University Of California | Hydrogel toxin-absorbing or binding nanoparticles |
US10632070B2 (en) | 2014-03-20 | 2020-04-28 | The Regents Of The University Of California | Hydrogel toxin-absorbing or binding nanoparticles |
US11007147B2 (en) | 2014-03-20 | 2021-05-18 | The Regents Of The University Of California | Hydrogel toxin-absorbing or binding nanoparticles |
US10610493B2 (en) | 2015-04-29 | 2020-04-07 | The Regents Of The University Of California | Detoxification using nanoparticles |
US11357736B2 (en) | 2015-04-29 | 2022-06-14 | The Regents Of The University Of California | Detoxification using nanoparticles |
WO2020203965A1 (ja) * | 2019-03-30 | 2020-10-08 | 国立大学法人九州大学 | 細胞接着用粒子及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
FR2839260A1 (fr) | 2003-11-07 |
WO2003092657A1 (fr) | 2003-11-13 |
CA2483707C (fr) | 2012-03-06 |
EP1507517A1 (fr) | 2005-02-23 |
AU2003249390A1 (en) | 2003-11-17 |
JP4819356B2 (ja) | 2011-11-24 |
EP1507517B1 (fr) | 2017-03-08 |
FR2839260B1 (fr) | 2005-02-25 |
CA2483707A1 (fr) | 2003-11-13 |
ES2626204T3 (es) | 2017-07-24 |
JP2011153143A (ja) | 2011-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011153143A (ja) | 細胞及び作用物質を担持する微小粒子 | |
US9579287B2 (en) | Microparticles supporting cells and active substances | |
US11890303B2 (en) | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse | |
Orive et al. | Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates | |
Yu et al. | The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat | |
Wang et al. | Therapeutic cell delivery and fate control in hydrogels and hydrogel hybrids | |
Murua et al. | Cell microencapsulation technology: towards clinical application | |
US8197553B2 (en) | Composite scaffolds and methods using same for generating complex tissue grafts | |
Tatard et al. | Pharmacologically active microcarriers: a tool for cell therapy | |
CN104470505B (zh) | 微球组合物及其制备方法和应用 | |
Büyüköz et al. | Nanofibrous gelatine scaffolds integrated with nerve growth factor‐loaded alginate microspheres for brain tissue engineering | |
Leung et al. | Tissue transplantation by stealth—coherent alginate microcapsules for immunoisolation | |
Shanbhag et al. | Neural progenitor cells grown on hydrogel surfaces respond to the product of the transgene of encapsulated genetically engineered fibroblasts | |
Zilberman et al. | Polymer‐encapsulated engineered adult mesenchymal stem cells secrete exogenously regulated rhBMP‐2, and induce osteogenic and angiogenic tissue formation | |
Kim et al. | Biomaterials for stem cell therapy for cardiac disease | |
Sapin et al. | Development of new polymer-based particulate systems for anti-glioma vaccination | |
Mendez et al. | Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microspheres | |
Orive et al. | Recent advances in the use of encapsulated cells for effective delivery of therapeutics | |
Filipovic-Gric et al. | Microparticles with neuroactive agents | |
Tai | The microencapsulation of cells: immunological isolation and the application in somatic gene therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100331 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110425 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110805 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110901 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140909 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4819356 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |